Double-hit B-cell lymphomas.
By S. Aukema, R. Siebert, E. Schuuring, G. V. van Imhoff, H. Kluin-Nelemans, Evert-Jan G. Boerma, P. Kluin. Blood, 2011
676 citations recorded by the source corpus.
Subfields: Genetics, Neurology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/03fa64ba9fb30c8639e3db2ab48c55b6753352c4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- S. Swerdlow
- Shimin Hu
- A. Ferreri
- A. Tzankov
- S. Montes-Moreno
- G. Bhagat
- E. Hsi
- R. Miranda
Citations in the corpus
- WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2017, background): “Another subset (also accounting for -50% of cases) shows a morphology that mim¬ ics that of BL, or has features intermediate between DLBCL and BL (193,194,3143, 3712,3846).”
- MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. (2013, background): “Despite their clinical aggressiveness, almost all cases of MYC/BCL2 double-hit lymphoma are of the GCB subtype, a generally favorable prognostic group, illustrating an important discordance between clinical behavior and cell-of-origin (COO) subtypes.(14,16,17) More recently, others have extended the”